Dosing considerations for rufinamide in patients with Lennox –Gastaut syndrome: Phase III trial results and real-world clinical data

Lennox –Gastaut syndrome (LGS) is one of the most severe forms of childhood-onset epilepsy, accounting for approximately 1% to 4% of all childhood epilepsy cases, with peak onset occurring between the ages of 3 and 5 years [1–3]. Although the etiology of LGS is frequently unknown, the condition is char acterized by a triad of symptoms, including impairment of cognitive function, slow spike-and-wave complexes on electroencephalogram (EEG) recordings, and multiple seizure types, making it particularly difficult to control [1,3].

Source: Seizure: European Journal of Epilepsy - February 15, 2017 Category: Neurology Authors: Sanjeev Kothare, Gerhard Kluger, Rajesh Sachdeo, Betsy Williams, Omar Olhaye, Carlos Perdomo, Francesco Bibbiani Source Type: research